Author
Listed:
- Xiao-Xian Xu
(The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China)
- Jian-Song Zhou
(The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China)
- Shu-Hui Yuan
(The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China)
- Hua Yu
(The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China)
- Han-Mei Lou
(The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China)
Abstract
Human papillomavirus (HPV) are firmly established as the principal causative agent for cervical carcinoma. Current vaccines may provide some protection for women from cervical carcinoma linked to HPV genotype 16 and 18. This may be the best vaccine for Western women, but the geographical variation in HPV distributions may not make it the most appropriate vaccine for China or Asia. This study provided an observational, retrospective, hospital-based cross-sectional study on the distribution of HPV genotypes among 5410 women with invasive cervical cancer (ICC) or cervical intraepithelial neoplasia (CIN). Overall, the positive rates of the four HPV types included in current prophylactic vaccines were counted, the two high-risk types (HPV-16 and -18) covered by current vaccines represented 66.9% of women with squamous cancer, 55.0% with adenocarcinoma, 64.9% with adenosquamous carcinoma and 77.4% of other type ICC, as well as 59.5% of CIN III, 45.0% of CIN II and 38.1% of CIN I cases. As expected, two low-risk types (HPV-6 and -11) included in the quadrivalent vaccine did not show good coverage data. Particularly worth mentioning is the fact that the addition of HPV-52 and -58 to the vaccine cocktail would increase cancer protection in our population, potentially preventing up to beyond 16% of squamous/adenosquamous carcinoma and other type of cervical cancers, and 7.75% of adenocarcinomas. It might also potentially reduce the rate of CIN III by a further 28.6% and CIN II and I by a third. This study established the baseline for surveillance in Zhejiang Province, and provides data for further vaccine designs: a quadrivalent HPV vaccine covering HPV-16/-58/-18/-52, would be more welcome in our region in the forthcoming year compared to the currently available vaccine.
Suggested Citation
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:12:y:2015:i:9:p:10794-10805:d:55161. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.